Literature DB >> 8482195

Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori.

K Jaskiewicz1, J A Louw, I N Marks.   

Abstract

Thirty-six patients with nonhealing or recurrent duodenal ulcers (DU) were treated with omeprazole; 20 mg/day for one month followed by triple therapies (metronidazole, 400 mg three times a day, tetracycline, 500 mg four times a day with either colloidal bismuth, 120 mg four times a day or sucralfate 1 g four times a day. At least two gastric mucosal samples were collected from the antral portion of the stomach and from the duodenum before and immediately after omeprazole therapy and four weeks after completion of triple therapies. Samples were fixed in buffered formaldehyde and glutaraldehyde and examined histologically and histochemically for inflammation, density of H. pylori colonization, and immunohistochemically for the density of gastrin-secreting cells, immunoglobulins (IgA, IgG, IgM), kappa and lambda light chains and T-lymphocyte population. H. pylori colonization of the antral mucosa before treatment was noted in 100% and active gastritis in 86% of patients. The histologically assessed clearance rate after omeprazole treatment was 47.3%, and after triple therapies, 69.5%. The prevalence of gastritis was observed in 63.9% and 33.3% respectively. All therapies were associated with an accumulation of serous fluid, increased population of lymphocytes and plasma cells, and secretion of immunoglobulins, particularly IgG and IgM in the upper part of the lamina propria. These changes, together with increased numbers of T lymphocytes within the crypt epithelium and the lamina propria, were associated with the presence of H. pylori organisms.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482195     DOI: 10.1007/bf01295924

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  Serum pepsinogen I and gastrin concentrations in children positive for Helicobacter pylori.

Authors:  G Oderda; D Vaira; D Dell'Olio; J Holton; M Forni; F Altare; N Ansaldi
Journal:  J Clin Pathol       Date:  1990-09       Impact factor: 3.411

2.  The association of Campylobacter pylori with mucosal pathological changes in a population at risk for gastric cancer.

Authors:  K Jaskiewicz; H D Louwrens; C W Woodroof; M J van Wyk; S K Price
Journal:  S Afr Med J       Date:  1989-05-06

Review 3.  Drug therapy for Helicobacter pylori infection: problems and pitfalls.

Authors:  Y Glupczynski; A Burette
Journal:  Am J Gastroenterol       Date:  1990-12       Impact factor: 10.864

4.  Trophic effects of gastrin.

Authors:  R Håkanson; F Sundler
Journal:  Scand J Gastroenterol Suppl       Date:  1991

5.  Immune response of the gastric mucosa to Campylobacter pylori.

Authors:  J I Wyatt; B J Rathbone
Journal:  Scand J Gastroenterol Suppl       Date:  1988

Review 6.  Omeprazole. Gastrin and gastric endocrine cell data from clinical studies.

Authors:  R G Berlin
Journal:  Dig Dis Sci       Date:  1991-02       Impact factor: 3.199

7.  Lymphocytic gastritis--relationship to Campylobacter pylori infection.

Authors:  M F Dixon; J I Wyatt; D A Burke; B J Rathbone
Journal:  J Pathol       Date:  1988-02       Impact factor: 7.996

Review 8.  Campylobacter pylori and peptic ulcer disease.

Authors:  D Y Graham
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

9.  Histology of gastric biopsies from peptic ulcer patients before and after short-term treatment with omeprazole or H2-receptor antagonists.

Authors:  H F Helander; M Simonsson; F Sundler; K Rutgersson; K G Helander; S Eriksson
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

10.  Cure of duodenal ulcer associated with eradication of Helicobacter pylori.

Authors:  E A Rauws; G N Tytgat
Journal:  Lancet       Date:  1990-05-26       Impact factor: 79.321

View more
  3 in total

1.  Increased macrophage infiltration of gastric mucosa in Helicobacter pylori-infected children.

Authors:  A E Whitney; T S Emory; A M Marty; P A O'Shea; G W Newman; B D Gold
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

2.  Clinical application of gastric histology to monitor treatment of dual therapy in H. pylori eradication.

Authors:  H B Yang; B S Sheu; I J Su; C H Chien; X Z Lin
Journal:  Dig Dis Sci       Date:  1997-09       Impact factor: 3.199

Review 3.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.